Jump Financial LLC Buys New Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Jump Financial LLC bought a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 20,400 shares of the company’s stock, valued at approximately $134,000. Jump Financial LLC owned about 0.06% of Lexeo Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Lexeo Therapeutics during the fourth quarter worth approximately $46,000. JPMorgan Chase & Co. lifted its position in Lexeo Therapeutics by 135.6% during the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Lexeo Therapeutics during the fourth quarter worth approximately $72,000. Wells Fargo & Company MN lifted its position in Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company’s stock worth $73,000 after acquiring an additional 3,714 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Lexeo Therapeutics by 19.6% in the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock valued at $166,000 after buying an additional 4,127 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $3.55 on Tuesday. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $117.85 million, a price-to-earnings ratio of -1.12 and a beta of 1.52. The business has a 50-day moving average of $2.97 and a 200-day moving average of $5.51.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. As a group, equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Royal Bank of Canada reduced their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Finally, Chardan Capital dropped their target price on Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, April 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $22.20.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.